We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Developmental Milestones Sample Clauses

Developmental MilestonesBorrower shall ensure that: (a) Not later than September 30, 2016, at least one patient shall have enrolled in a Phase 3 clinical trial for KD019-101 for the treatment of autosomal dominant polycystic kidney disease. (b) Not later than December 31, 2016, at least one patient shall have enrolled in a Phase 2b clinical trial for KD025-205 for the treatment of psoriasis. (c) Not later than December 31, 2016, the FDA shall have accepted an NDA for a 505(b)(2) for trientine for the treatment of Xxxxxx’x Disease.
Developmental Milestones. Novartis will notify Xxxxx of the first achievement of any of the Milestone Events set forth below within [***] after their achievement. In addition to (and not in lieu of) royalty payments due under this Agreement, Novartis shall pay to Xxxxx the following one-time, non-refundable, non-recoupable, non- creditable milestone payments no later than [***] after receipt of an invoice for the same, which will be issued following receipt of Novartis’ notice, via wire transfer in immediately available funds to the account specified in writing by Xxxxx: [***] $ [*** ] [***] $ [*** ] [***] $ [*** ] Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Developmental Milestones. Developmental Milestones by COMPANY for a LICENSED PRODUCT in accord with Paragraph 5.3 are as follows: Complete IND enabling study 2020 Initiate animal toxicology study last half 2020 File IND first half 2021 Complete PHASE I CLINICAL TRIAL first half of 2022 Commence PHASE II CLINICAL TRIAL 2024 Commence PHASE III CLINICAL TRIAL 2026 Regulatory approval, US or foreign equivalent 2026
Developmental Milestones. (a) Borrower shall have received approval from the FDA to market a generic trientine hydrochloride formulation (based upon the development program currently known as KD034) by December 31, 2019. (b) Borrower shall have fully enrolled its KD025-213 clinical study of 126 total patients for KD025 for the treatment of Chronic Graft-Versus-Host Disease (cGVHD) by December 31, 2019.
Developmental MilestonesSubject to Section 4.2(c) below, within ninety (90) days of the first achievement of each of the milestone events set forth in the table below by Provention or any Related Party, Provention shall provide Vactech with written notice of such achievement and shall pay to Vactech the corresponding one-time milestone payment set forth below (each a “Developmental Milestone”):
Developmental Milestones. The Developmental Milestones under Paragraph 3.4 are: Within thirty (30) days of the issuance of the first U.S. Patent from the PATENT RIGHTS Company will pay to JHU Twenty-five-thousand ($25,000) U.S. Dollars. Within thirty (30) days of the FIRST COMMERCIAL SALE of an Albumin-Bound Protein/Peptide Complex-based research product, company will pay to JHU Twenty-five Thousand ($25,000) U.S. Dollars. Within thirty (30) days of the submission of the first Albumin-Bound Protein/Peptide Complex-based test for regulatory approval in any country, company will pay to JHU One-hundred-thousand ($100,000) U.S. Dollars. Within thirty (30) days of FIRST COMMERCIAL SALE of an Albumin-Bound Protein/Peptide Complex-based approved diagnostic product, company will pay to JHU One-hundred-seventy-five Thousand ($175,000) U.S. Dollars.
Developmental Milestones. (a) Not later than December 31, 2017, at least one patient shall have enrolled in a Phase 3 clinical trial for KD019-101 for the treatment of autosomal dominant polycystic kidney disease. (b) Not later than December 31, 2016, at least one patient shall have enrolled in a Phase 2b clinical trial for KD025-205 for the treatment of psoriasis. (c) Not later than December 31, 2016, the Borrower shall have submitted to FDA for acceptance an NDA for a 505(b)(2) or an abbreviated new drug application for trientine for the treatment of Xxxxxx’x Disease. (d) Not later than June 30, 2017, the Borrower shall have, for the purposes of advancing IND #069215 towards FDA approval, initiated a new clinical trial for KD019 (separate and distinct from the clinical trial referred to in clause (a) above) for the treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations and brain metastases or leptomeningeal disease.” (d) Section 10 of the Existing Credit Agreement is hereby amended by adding new Section 10.03 to read as follows:
Developmental MilestonesWith respect to each Royalty Bearing Product, Licensee shall make the following non-creditable, non-refundable developmental milestone payments to DFCI within [***] days of the occurrence of the following events, whether Licensee, an Affiliate, Sublicensee, a permitted assignee, or a successor achieves the events. For the avoidance of doubt, all development milestone payments are payable [***]. [***] $[***] [***] $[***] [***] $[***] [***] $[***] [***] $[***] [***] $[***]
Developmental Milestones. Within 30 business days of the achievement of each of the milestone events set forth in the table below (each a “Developmental Milestone”) by Virpax or any Related Party, Virpax shall provide Lipocure with written notice of such achievement and shall pay to Lipocure the corresponding one-time milestone payment set forth next to the applicable milestone in the table below:
Developmental Milestones. Company shall pay to JHU Developmental Milestones as set forth in Exhibit A. The Developmental Milestone payments shall be due, without the need for invoice from JHU, within Ninety (90) days of Company meeting the requirement of each milestone.